DESPITE LIMITED BENEFIT, FUNDUSCOPIC EXAMINATION SHOULD BE CONTINUED FOR HYPERTENSION*

Öz

funduscopic examination should be continued for HT until demonstration of some more accurate follow up criteria. their specificities for HT are probably higher, particularly for hypertensive crises. Therefore, although limited benefit, Additionally, although the lower incidences and even additional atherosclerotic backgrounds of grade III and IV HRs, benefits of funduscopic examination in management of HT due to limited number of available parameters in this field. higher prevalence of grade II HRs in the HT group indicate the effects of HT on retinal vasculature, and probable Conclusion: Although HR is not a specific sign of HT, the significantly lower prevalence of grade 0 and significantly p<0.01) in the HT group.
significantly lower (55.4% versus 32.6%, p<0.01) and grade II HR was significantly higher (4.0% versus 13.0%, detected in any group. Differences were nonsignificant according to prevalence of grade I HR whereas grade 0 HR was 28.2%, p<0.01) were significantly higher in the HT group. No case of grade III or IV hypertensive retinopathy (HR) was the groups, whereas prevalences of obesity (27.0% versus 54.3%, p<0.001) and hypertriglyceridemia (13.5% versus gender distribution, and prevalences of smoking, diabetes mellitus, hyperbetalipoproteinemia, and dyslipidemia between Results: We studied 74 cases with NT and 46 with HT. There were nonsignificant differences according to the mean age, Medicine Polyclinic. Methods: The study was performed on consecutive check up patients with normotension (NT) and HT in Internal mainstay for prevention of cardiovascular diseases. B

Anahtar Kelimeler

• Hypertension
• hypertensive retinopathy
• funduscopic examination

DESPITE LIMITED BENEFIT, FUNDUSCOPIC EXAMINATION SHOULD BE CONTINUED FOR HYPERTENSION

Öz

Amaç: Hipertansiyon (HT), ciddi kardiyovasküler olay riskini arttırmaktadır, bu sebeple kan basıncı kontrolü
kardiyovasküler hastalıkların önlenmesinde ana unsurdur.
Metotlar: Çalışma, İç Hastalıkları Polikliniùinde ardı sıra başvuran normal tansiyon (NT) vakası ve HT hastalarında
yapıldı.
Sonuçlar: Yetmiş dört NT vakası ve 46 HT hastası çalışmaya alındı. Gruplar arasında ortalama yaş, cinsiyet ve sigara,
diyabet, hiperbetalipoproteinemi ve dislipidemi prevelansları açısından istatistiksel olarak anlamlı bir farklılık yoktu. Ancak
obezite (%27.0’a karşılık %54.3, p<0.001) ve hipertrigliseridemi (%13.5’e karşılık %28.2, p<0.01) prevelansları HT
grubunda anlamlı şekilde yüksekti. Her iki grupta da hiçbir grade III veya IV hipertansif retinopati (HR) vakasına
rastlanmadı. Gruplar arasındaki fark grade I HR prevelansı açısından anlamsızdı, ancak grade 0 HR prevelansı HT
grubunda anlamlı şekilde düşük iken (%55.4’e karşılık %32.6, p<0.01), grade II HR prevelansı anlamlı şekilde yüksekti
(%4.0’a karşılık %13.0, p<0.01).
Özet: Her ne kadar HR, HT’a spesifik bir bulgu deùilse de, HT grubunda tespit edilen grade 0 HR prevelansının anlamlı
düşüklüùü ve grade II HR prevelansının anlamlı yüksekliùi HT’un göz damarlanması üzerine olan etkilerini göstermekte
ve bu alanda mevcut kullanılabilir takip parametreleri sayısının kısıtlı olması nedeniyle muhtemel faydasına işaret
etmektedir. Ek olarak, her ne kadar toplumdaki insidanslarının düşük olması ve ilave ateroskleroz zeminlerine raùmen,
grade III ve IV HR’nin HT için, özellikle de hipertansif krizler için spesifisitesi muhtemelen yüksektir. Bu sebeple, her ne
kadar faydası kısıtlıysa da yeni bazı daha etkili takip kriterlerinin bulunmasına kadar HT hastalarının tanı ve takibinde
göz dibi muayenesine devam edilmelidir. 

Anahtar Kelimeler

• Hipertansiyon
• hipertansif retinopati
• göz dibi muayenesi

Kaynakça

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn
2. S, Murray CJ: Comperative Risk Assessment
3. Collaborating Group. Selected major risk factors
4. and global and regional burden of disease.
5. Lancet 2002; 360: 1347-1360.
6. Chobanian AV, Bakris GL, Black HR, Cushman
7. WC, Green LA, Izzo JL Jr, et al. Seventh Report
8. of the Joint National Committee on Prevention,

9. Detection, Evaluation, and Treatment of High
10. Blood Pressure. Hypertension 2003; 42: 1206-
11. -
12. Helvaci MR, Seyhanli M. What a high
13. prevalence of white-coat hypertension in society!
14. Intern Med 2006; 45: 671-674.
15. Akdeniz B, Goldeli O, Baris N. Blood pressure
16. control rates in hypertensive patients and their
17. determining factors in two urban regions of
18. Izmir. Anadolu Kardiyol Derg 2005; 5: 133-134.
19. Turkish
20. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion
21. JM, Mancia G, et al. European Society of
22. Hypertension recommendations for
23. conventional, ambulatory and home blood
24. pressure measurement. J Hypertens 2003; 21:
25. –848.
26. Helvaci MR, Kaya H, Seyhanli M, Cosar E.
27. White Coat Hypertension Is Associated with a
28. Greater All-cause Mortality. J Health Sci 2007;
29. : 156-160.
30. Helvaci MR, Kaya H, Yalcin A, Kuvandik G.
31. Prevalence of white coat hypertension in
32. underweight and overweight subjects. Int Heart J
33. ; 48: 605-613.
34. Mandava N, Yannuzzi LA. Hypertensive
35. Retinopathy. In: Regillo CD, Brown GC, Flynn
36. HW Jr, eds. Vitreoretinal Disease: The
37. Essentials. New York: Thieme; 1999: 193-196.
38. Third Report of the National Cholesterol
39. Education Program (NCEP) Expert Panel on
40. Detection, Evaluation, and Treatment of High
41. Blood Cholesterol in Adults (Adult Treatment
42. Panel III) final report. Circulation 2002; 17:106:
43. -3421.
44. Ohkubo T, Asayama K, Kikuya M, Metoki H,
45. Hoshi H, Hashimoto J, et al. How many times
46. should blood pressure be measured at home for
47. better prediction of stroke risk? Ten-year followup
48. results from the Ohasama study. J Hypertens
49. ; 22: 1099–1104.
50. Ridker PM, Libby P. Risk Factors for
51. Atherothrombotic Disease. In Douglas P. Zipes,
52. Peter Libby, Robert O. Bonow, Eugene
53. Braunwald (eds): Braunwald’s Heart Disease: A
54. Textbook of Cardiovascular Medicine 7th Ed.
55. Philadelphia, Pennsylvania, Elsevier Saunders
56. ; 939-958.
57. Cuspidi C, Salerno M, Salerno DE, Meani S,
58. Valerio C, Esposito A, et al. High prevalence of
59. retinal vascular changes in never-treated
60. essential hypertensives: an inter- and intraobserver
61. reproducibility study with nonmydriatic
62. retinography. Blood Press 2004; 13:
63. -30.
64. Van den Born BJ, Schlingemann RO, Hoekstra
65. JB, van Montfrans GA. Routine funduscopic
66. examination in hypertensive patients not useful.
67. Ned Tijdschr Geneeskd 2004; 148: 464-468.
68. Raczynska K, Potaz P, Aleszewicz-Baranowska J.
69. Epidemiology of hypertensive retinopathy in
70. young patients after coarctation of the aorta
71. repair. Klin Oczna 2004; 106: 456-459.
72. Fuchs FD, Maestri MK, Bredemeier M, Cardozo
73. SE, Moreira FC, Wainstein MV, et al. Study of
74. the usefulness of optic fundi examination of
75. patients with hypertension in a clinical setting. J
76. Hum Hypertens 1995; 9: 547-551.
77. Takiuchi S, Kamide K, Miwa Y, Tomiyama M,
78. Yoshii M, Matayoshi T, et al. Diagnostic value of
79. carotid intima-media thickness and plaque score
80. for predicting target organ damage in patients
81. with essential hypertension. J Hum Hypertens
82. ; 18: 17-23.
83. Luft FC, Agrawal B. Microalbuminuria as a
84. predictive factor for cardiovascular events. J
85. Cardiovasc Pharmacol 1999; 33: 11-15.
86. Palatini P, Penzo M, Bongiovi S, Canali C,
87. Pessina AC. Role of ophthalmoscopy in arterial
88. hypertension: a problem revisited. Cardiologica
89. ; 36: 713-722.
90. Besharati MR, Rastegar A, Shoja MR, Maybodi
91. ME. Prevalence of retinopathy in hypertensive
92. patients. Saudi Med J 2006; 27: 1725-1728.
93. Helvaci MR, Ozcura F, Kaya H, Yalcin A.
94. Funduscopic Examination Has Limited Benefit
95. for Management of Hypertension. Int Heart J
96. ; 48: 187-194.
97. Skalina ME, Annable WL, Kliegman RM,
98. Fanaroff AA. Hypertensive retinopathy in the
99. newborn infant. J Pediatr 1983; 103: 781-786.